RPRXRoyalty Pharma plc
Is the price fair?
Neither cheap nor expensive: nothing decisive, though rich vs its sector.
In its normal range: P/E 30.3 vs a 22.6 median over 22 quarters (+34% vs median).
Sector median 22.6× across 130 covered peers. EV/EBIT counts debt as part of the price, so a cash-rich and a borrowed company can be compared on the same footing.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What RPRX's price assumes
Royalty Pharma plc trades at 30.3× earnings against 18.8× for the median Biotechnology name, more expensive than its own group.
Trailing P/E · Biotechnology median 18.8 · 1.61× the median: the market pays up for this one
- Price / sales
- 12.4
Price / sales · today's price, trailing year to Jun 30, 2026
- Price / book
- 3.22
Price / book · today's price, trailing year to Jun 30, 2026
- EV / sales
- 15.6
EV / sales
Details›
- Price / booktoday's price, trailing year to Jun 30, 2026
- 3.22
- EV / EBITtoday's price, trailing year to Jun 30, 2026
- 26.2
- EV / salestoday's price, trailing year to Jun 30, 2026
- 15.6
- Healthcare median P/E509 names
- 26.2
- Biotechnology median P/E244 names
- 18.8
- Market capitalisation
- $31.5B
| Method | Per share |
|---|---|
| Its own P/E history, lower quartile | $29.23 |
| Its own P/E history, median | $42.49 |
| Its own P/E history, upper quartile | $58.86 |
| 52-week range | $34.37 – $63.98 |
| Today | $56.90 |
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.